SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, has appointed veteran medical technology finance executive Sarah M. Romano as chief financial officer, effective August 3, 2026. Romano brings more than two decades of experience in public-company finance, capital markets, and medical technology, having raised more than $100 million during her career. The appointment comes as SS Innovations continues pursuing U.S. FDA clearance for its SSi Mantra surgical robotic system while expanding internationally.
Romano joins SS Innovations after serving as chief financial officer at Vicarious Surgical, another developer of robotic surgical technologies, where she oversaw financial and operational initiatives designed to reduce cash burn and strengthen the company’s balance sheet. Her expertise in capital markets and medtech finance is expected to be instrumental as SS Innovations advances its regulatory initiatives and broader commercialization of the SSi Mantra platform. The company is preparing for U.S. Food and Drug Administration review, a critical step toward entering the U.S. market.
Alongside regulatory progress, SS Innovations is emphasizing surgeon education through its SS International Centre for Robotics Surgery (SSICRS). The company recently graduated the inaugural class of its cardiac robotic surgery training program, which welcomed 33 healthcare professionals from seven countries. This underscores the company’s focus on ensuring that surgeons are well-trained to use its technology, which is key to successful adoption and patient outcomes.
The global expansion of robotic surgery is gaining momentum, and SS Innovations is positioning itself to compete with established players. The SSi Mantra system is designed to provide a versatile platform for various surgical procedures, and international expansion is already underway. The company’s newsroom at https://ibn.fm/SSII provides updates on these developments.
Romano’s appointment signals a strategic move to strengthen financial oversight and investor confidence as SS Innovations navigates the capital-intensive process of FDA approval and global market entry. Her experience in raising capital and managing public-company finances will be critical for funding ongoing operations and expansion.
The company also cautions that forward-looking statements involve risks and uncertainties, as detailed in its SEC filings. For more information, the full terms of use and disclaimers are available at http://IBN.fm/Disclaimer.
